Full Length Research Article
Retraction in process: Exploring Natural Compounds as Promising Matrix Metalloproteinase-2 inhibitors for Cancer Management: A Biocomputational Study
Akram Ahmed Aloqbi
Adv. life sci., vol. 11, no. 3, pp. 674-678, August 2024
*- Corresponding Author: Akram Ahmed Aloqbi (aaaloqbi@uj.edu.sa)
Authors' Affiliations
[Date Received: 09/02/2024; Date Revised: 14/03/2024; Date Published: 10/07/2024]
Editorial Expression of Concern:
18 May 2025: Following publication of this paper, the internal audit (consequent to concerns on quality raised by Web of Science) notified Advancements in Life Sciences about problems in use of English language. By this Editorial Expression of Concern, we alert the scientific community of the errors as we reconcile the records.
Editorial Note:
28 May 2025: While reconciling the record of Turnitin originality analysis, 49% content of this article was found generated using AI tool/s without clear disclosure along with similarity on more than 4% with at least one source published prior to this article.
Editorial board of Advancements in Life Sciences has started the process of retracting this article due to the above post-publication findings. The process shall be concluded after registering responses from the authors. Meanwhile, full text of the article shall remain unavailable for citations (this notice has been updated following insights derived from relevant COPE cases and the industry standards).
Abstract
Introduction
Methods
Results
Discussion
References
Abstract
Background: Matrix metalloproteinase-2 (MMP2) plays a role in breaking down the components of the extracellular matrix, which allows cancer cells to advance and invade. Therefore, the inhibition of MMP2 shows potential as a promising strategy for treating cancer.
Methods: This study employed computational screening to identify MMP2 inhibitors from a collection of 2,405 natural compounds. GLXC-26716, the co-crystal ligand of MMP2, served as the positive control. Virtual screening was performed using PyRx 8.0 software to find molecules that might inhibit the active site of MMP2.
Results: The virtual screening process has identified five potential candidates: ZINC000000001412, ZINC000001612328, ZINC000001614079, ZINC000000119988, and ZINC0000000047553. These candidates were selected based on their strong binding affinities and interactions with MMP2. These compounds, which adhere to Lipinski's Rule of Five and have significant physicochemical properties, show promise as MMP2 inhibitors.
Conclusion: The finding of this study indicates a preliminary investigation into an innovative approach for managing cancer that inhibits the invasion and dissemination of cancer cells.
Keywords: Matrix Metalloproteinase-2; Natural compounds; Cancer; Virtual screening
